Figure 2From: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer JMJD6 expression and prognosis in intrinsic subtypes of breast cancer. Box plots of JMJD6 expression demonstrate (A) higher JMJD6 probeset intensity (log2) in ER- tumors compared with ER+ tumors, with P < 0.001 by Mann-Whitney Rank Sum test; and (B) highest JMJD6 probeset intensity (log2) in claudin-low and basal subtypes, followed by HER2-enriched and LumB subtypes, and lowest in LumA subtypes. The Dunn method was used to perform pairwise multiple comparison among the subtypes. *P < 0.05 between a pair of subtypes. Dots of boxplots (A, B) represent outliers in the 90th and 10th percentiles. Kaplan-Meier survival curves based on below-median (low) and above-median (high) JMJD6 expression are shown for (C) ER+ patients, (D) patients of LumA subtype, (E) patients of LumB subtype, and (F) ER+, tamoxifen-treated patients. The numbers in the parentheses equal patient numbers in each group, and the log rank P value is indicated at the bottom left of each figure.Back to article page